TTUHSC School of Pharmacy
HomeSOPGraduate Program in Pharmaceutical Sciences (GPPS)Current Graduate Students

Verma, Kshitij

Pharmaceutical Sciences

verma
  • Graduate Student / Research Assistant

Lab Phone: 806-414-9259
E-Mail: kshitij.verma@ttuhsc.edu
Mail Address: 1300 S Coulter
Amarillo, TX 79106-1712

Biography

Kshitij Verma completed his undergraduate degree in Pharmacy from Devi Ahilya Vishwavidyalaya (DAVV) University, Indore, India in 2012. Thereafter, he joined the department of Pharmacology and Toxicology at the University of Missouri - Kansas City as a graduate PhD student in the Fall of 2012. In the Summer of 2013, Kshitij transferred to the Texas Tech University Health Sciences Center to join the Graduate Program in Pharmaceutical Sciences as a PhD student. Currently, he is working in the laboratory of Dr. Paul Trippier with the Department of Pharmaceutical Sciences, and his research is focused on the synthesis of novel anti-cancer molecules targeted towards the enzyme AKR1C3 in prostate cancer and Acute Myelocytic Leukemia (AML).

Education:

  • BPharm: Devi Ahilya Vishwavidyalaya (DAVV), India, 2012

Research Interests:

Synthesis and antineoplastic evaluation of novel anti-cancer molecules targeted towards the enzyme Aldo-Keto Reductase 1C3 (AKR1C3) in prostate cancer and Acute Myelocytic Leukemia (AML).

Publications:

  • Wang H, Huwaimel B, Verma K, Miller J, Germain TM, Kinarivala N, Pappas D, Brookes PS, Trippier PC. Synthesis and Antineoplastic Evaluation of Mitochondrial Complex II (Succinate Dehydrogenase) Inhibitors Derived from Atpenin A5. ChemMedChem. 2017 May 18. doi: 10.1002/cmdc.201700196. [Epub ahead of print]
  • Kshitij Verma, Tianzhu Zang, Nehal Gupta, Travor M. Penning, and Paul C. Trippier. Selective AKR1C3 Inhibitors Potentiate Chemothrapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. ACS Med. Chem. Lett. 2016 Jun 22;7(8):774-9. doi: 10.1021/acsmedchemlett.6b00163. eCollection 2016.
  • Zang T1, Verma K1, Chen M, Jin Y, Trippier PC, Penning TM. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Chem Biol Interact. 2015 Jun 5; 234:339-48. Epub 2014 Dec 31. [1=first authors]

Presentations:

  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Discovery of (E)-(4-(3-methylbut-2-en-1-yl)-3-(3-phenylpropanamido)cinnamic acid as Highly Potent and Selective Inhibitor of AKR1C3 for the Treatment of Castration-Resistant Prostate Cancer and Acute Myeloid Leukemia". 254th American Chemical Society, National Meeting & Exposition, Division of Medicinal Chemistry, Washington, D.C.; August 2017.
  • Podium Presentation: Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, synthesis and evaluation of small-molecule inhibitors of AKR1C3 to manage castration-resistant prostate cancer (CRPC) and acute myeloid leukemia (AML)". Sixteenth Annual Research Days, TTUHSC School of Pharmacy, Amarillo TX; June 2017.
  • Invited Speaker: Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, Synthesis and Evaluation of Small-Molecule Inhibitors of AKR1C3 to Manage Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)". National Institutes of Health/National Cancer Institute, Graduate Student Recruiting Program, Bethesda, MD; May 2017.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Inhibitors of AKR1C3 as Novel Therapeutics for the Treatment of Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)". American Association of Pharmaceutical Scientists, National Biotechnology Conference, San Diego, CA; May 2017.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, Synthesis and Evaluation of Inhibitors of Type 5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) as Novel Therapeutics to Manage Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)". Society of Toxicology, Baltimore, MD; March 2017.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, Synthesis and Structure-Activity Relationship Optimization of Baccharin Derivatives for AKR1C3 Inhibition". American Association of Pharmaceutical Scientists, Denver, CO; November 2016.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, Synthesis and Evaluation of Inhibitors of Type 5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) as Novel Therapeutics to Manage Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)". American Association of Pharmaceutical Scientists, Denver, CO; November 2016.
  • Podium Presentation: Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Design, Synthesis and Evaluation of Inhibitors of Type 5 17β-Hydroxysteroid Dehydrogenase (AKR1C3) as Novel Therapeutics to Manage Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)". Lone Star Regional Chapter of the Society of Toxicology, Waco, TX; October 2016.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, Paul C. Trippier. “Design, Synthesis and Structure Activity Relationship Optimization of Baccharin Derivatives for AKR1C3 Inhibition.” Fifteenth Annual Research Days, TTUHSC School of Pharmacy, Amarillo, TX; June 2016.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, Paul C. Trippier. “Development of Novel Therapeutics for Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML): Synthesis and Evaluation of Selective AKR1C3 Inhibitors.” Fifteenth Annual Research Days, TTUHSC School of Pharmacy, Amarillo, TX; June 2016.
  • Podium Presentation: Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier. "Development of novel therapeutics for Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML): Design and Evaluation of selective AKR1C3 inhibitors." American Association of Pharmaceutical Scientists, National Biotechnology Conference, Boston, MA; May 2016.
  • Kshitij Verma, Tianzhu Zang, Trevor M. Penning, and Paul C. Trippier.  “Synthesis of Potent and Selective AKR1C3 Inhibitors for Acute Myeloid Leukemia Therapy”.  55th Annual Meeting and ToxExpo, Society of Toxicology, New Orleans, LA; March 2016.
  • Kshitij Verma, Tianzhu Zhang, Trevor Penning, and Paul C. Trippier.  "Synthesis and Antineoplastic Evaluation of Potent and Selective Inhibitors of AKR1C3".  Fourteenth Annual School of Pharmacy Research Days, TTUHSC, Amarillo, TX; June 2015.
  • Kshitij Verma, Tianzhu Zhang, Trevor Penning, and Paul C. Trippier. "Synthesis and Antineoplastic Evaluation of Potent and Selective Inhibitors of AKR1C3". America Chemical Society, Denver, CO; March 2015.
  • Kshitij Verma, Tianzhu Zhang, Trevor Penning, and Paul C. Trippier. "Synthesis and Antineoplastic Evaluation of Potent and Selective Inhibitors of AKR1C3." Thirteenth Annual SOP Research Days, TTUHSC, Amarillo, TX; June 2014.

Seminars:

  • 09/28/2016 "Development of AKR1C3 Inhibitors for the Treatment of Castration Resistant Prostate Cancer (CRPC) and Acute Myeloid Leukemia (AML)”
  • 09/30/2015 "Selective AKR1C3 Inhibitors for Acute Myeloid Leukemia (AML) Therapy" [Oral Qualifying Exam, public presentation]
  • 12/03/2014 "Selective AKR1C3 Inhibitors as Potential Leads for the Treatment of Castrate Resistant Prostate Cancer and Acute Myeloid Leukemia"

Awards/Scholarships:

  • American Association of Pharmaceutical Scientists (AAPS) Graduate Student Research Award in Drug Discovery and Development Interface (DDDI), AAPS Annual Meeting and Exposition, San Diego, CA; November 2017.
  • Travel Award, American Chemical Society, Division of Medicinal Chemistry [ACS DMC], 254th ACS National Meeting & Exposition, Washington, D.C.; August 2017. 
  • Best Podium Presenter, Senior Graduate Student, Dept. of Pharmaceutical Sciences, Sixteenth Annual Research Days, TTUHSC School of Pharmacy, Amarillo, TX; June 2017.
  • Invited Speaker, National Institutes of Health/National Cancer Institute, Graduate Student Recruiting Program, Bethesda, MD; May 2017.
  • American Association of Pharmaceutical Scientists (AAPS) Travelship from Drug Discovery and Development Interface Section (DDDI), AAPS National Biotechnology Conference, San Diego, CA; May 2017.
  • Graduate Student Winner - Best Abstract Award - Fourth Place, Dharm V. Singh Carcinogenesis Awards Fund, Society of Toxicology, March 2017. [selected Dec.2016]
  • Graduate Student Travel Support Award, Society of Toxicology, 56th Annual Meeting, Baltimore, MD, March 2017. [awarded Dec.2016]
  • American Association of Pharmaceutical Scientists (AAPS) Graduate Student Research Award in the Drug Discovery and Development Interface (DDDI), AAPS Annual Meeting and Exposition, Denver, CO, November 2016.
  • Mary Lou Clements-Mann Scholarship, TTUHSC GSBS, October 2016.
  • American Association of Pharmaceutical Scientists (AAPS), Podium Presentation & Biotechnology Graduate Student Research Award, AAPS National Biotechnology Conference, Boston, MA, May 2016.
  • Mary Lou Clements-Mann Scholarship, TTUHSC Graduate School of Biomedical Sciences, September 2015.
  • Outstanding Poster Presentation Award, Junior Graduate Student Category, Thirteenth Annual SOP Research Days, TTUHSC School of Pharmacy, Amarillo, TX, June 2014.

Memberships:

  • Society of Toxicology, September 2015-present.
  • American Association of Pharmaceutical Scientists, September 2015-present.
  • American Chemical Society, January 2015-present.
  • Graduate Student Association of Amarillo, 2013-present
©